Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017–2020
Issued Date
2023-09-01
Resource Type
ISSN
22137165
eISSN
22137173
Scopus ID
2-s2.0-85165939880
Pubmed ID
37422001
Journal Title
Journal of Global Antimicrobial Resistance
Volume
34
Start Page
113
End Page
118
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Global Antimicrobial Resistance Vol.34 (2023) , 113-118
Suggested Citation
Kiratisin P., Kempf M., Stone G., Utt E. Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017–2020. Journal of Global Antimicrobial Resistance Vol.34 (2023) , 113-118. 118. doi:10.1016/j.jgar.2023.06.005 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/88227
Title
Ceftazidime-avibactam and comparators against Pseudomonas aeruginosa isolates collected globally and in each geographical region between 2017–2020
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Objectives: The objective of this study was to assess the distribution and antimicrobial susceptibility of Pseudomonas aeruginosa isolates against ceftazidime-avibactam (CAZ-AVI) and a panel of comparator agents collected globally and in each region from 2017–2020 from the Antimicrobial Testing Leadership and Surveillance program. Methods: Susceptibility and minimum inhibitory concentration of all P. aeruginosa isolates were determined using broth microdilution methodology according to the Clinical and Laboratory Standards Institute guidelines. Results: Of the total 29746 isolates of P. aeruginosa collected, 20.9% were multidrug resistant (MDR), 20.7% were extremely drug resistant (XDR), 8.4% were CAZ-AVI-resistant (CAZ-AVI-R), and 3.0% were MBL-positive. Amongst the MBL-positive isolates, the proportion of VIM-positive isolates was highest (77.8%). The highest proportion of MDR (25.5%), XDR (25.0%), MBL-positive (5.7%), and CAZ-AVI-R (12.3%) isolates were in Latin America. Amongst the sources, the highest proportion of isolates were from respiratory sources (43.0%), and the majority of isolates were from non-intensive care unit wards (71.2%). Overall, all P. aeruginosa isolates (90.9%) showed high susceptibility to CAZ-AVI. However, MDR and XDR isolates were less susceptible to CAZ-AVI (≤60.7). The only comparators to which all isolates of P. aeruginosa showed good overall susceptibility were colistin (99.1%) and amikacin (90.5%). However, only colistin was active (≥98.3%) against all the resistant isolates. Conclusion: CAZ-AVI presents a potential treatment option against P. aeruginosa infections. However, active monitoring and surveillance, especially of the resistant phenotypes, is warranted for effective treatment of infections caused by P. aeruginosa.